Literature DB >> 25894200

A novel test to compare two treatments based on endpoints involving both nonfatal and fatal events.

Richard F Potthoff1, Susan Halabi2.   

Abstract

In a clinical trial comparing two treatment groups, one commonly-used endpoint is time to death. Another is time until the first nonfatal event (if there is one) or until death (if not). Both endpoints have drawbacks. The wrong choice may adversely affect the value of the study by impairing power if deaths are too few (with the first endpoint) or by lessening the role of mortality if not (with the second endpoint). We propose a compromise that provides a simple test based on the time to death if the patient has died or time since randomization augmented by an increment otherwise. The test applies the ordinary two-sample Wilcoxon statistic to these values. The formula for the increment (the same for experimental and control patients) must be specified before the trial starts. In the simplest (and perhaps most useful) case, the increment assumes only two values, according to whether or not the (surviving) patient had a nonfatal event. More generally, the increment depends on the time of the first nonfatal event, if any, and the time since randomization. The test has correct Type I error even though it does not handle censoring in a customary way. For conditions where investigators would face no easy (advance) choice between the two older tests, simulation results favor the new test. An example using a renal-cancer trial is presented.
Copyright © 2015 John Wiley & Sons, Ltd.

Entities:  

Keywords:  cancer progression; composite endpoints; log-rank test; mortality; two-sample Wilcoxon test

Mesh:

Year:  2015        PMID: 25894200      PMCID: PMC4503508          DOI: 10.1002/pst.1683

Source DB:  PubMed          Journal:  Pharm Stat        ISSN: 1539-1604            Impact factor:   1.894


  18 in total

1.  Combining mortality and longitudinal measures in clinical trials.

Authors:  D M Finkelstein; D A Schoenfeld
Journal:  Stat Med       Date:  1999-06-15       Impact factor: 2.373

2.  A GENERALIZED WILCOXON TEST FOR COMPARING ARBITRARILY SINGLY-CENSORED SAMPLES.

Authors:  E A GEHAN
Journal:  Biometrika       Date:  1965-06       Impact factor: 2.445

3.  Analysis of a binary composite endpoint with missing data in components.

Authors:  Hui Quan; Daowen Zhang; Ji Zhang; Laure Devlamynck
Journal:  Stat Med       Date:  2007-11-20       Impact factor: 2.373

Review 4.  Objective and perspective determine the choice of composite endpoint.

Authors:  George F Borm; Steven Teerenstra; Gerhard A Zielhuis
Journal:  J Clin Epidemiol       Date:  2008-02       Impact factor: 6.437

5.  Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206.

Authors:  Brian I Rini; Susan Halabi; Jonathan E Rosenberg; Walter M Stadler; Daniel A Vaena; Laura Archer; James N Atkins; Joel Picus; Piotr Czaykowski; Janice Dutcher; Eric J Small
Journal:  J Clin Oncol       Date:  2010-04-05       Impact factor: 44.544

6.  Assessing disease progression using a composite endpoint.

Authors:  Weng Kee Wong; Daniel E Furst; Philip J Clements; Jim B Streisand
Journal:  Stat Methods Med Res       Date:  2007-02       Impact factor: 3.021

Review 7.  Some issues with composite endpoints in clinical trials.

Authors:  George Y H Chi
Journal:  Fundam Clin Pharmacol       Date:  2005-12       Impact factor: 2.748

8.  Adjustment on the Type I Error Rate for a Clinical Trial Monitoring for both Intermediate and Primary Endpoints.

Authors:  Susan Halabi
Journal:  J Biom Biostat       Date:  2012-05-19

9.  Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma.

Authors:  Susan Halabi; Brian Rini; Bernard Escudier; Walter M Stadler; Eric J Small
Journal:  Cancer       Date:  2013-10-08       Impact factor: 6.860

10.  Enzalutamide in metastatic prostate cancer before chemotherapy.

Authors:  Tomasz M Beer; Andrew J Armstrong; Dana E Rathkopf; Yohann Loriot; Cora N Sternberg; Celestia S Higano; Peter Iversen; Suman Bhattacharya; Joan Carles; Simon Chowdhury; Ian D Davis; Johann S de Bono; Christopher P Evans; Karim Fizazi; Anthony M Joshua; Choung-Soo Kim; Go Kimura; Paul Mainwaring; Harry Mansbach; Kurt Miller; Sarah B Noonberg; Frank Perabo; De Phung; Fred Saad; Howard I Scher; Mary-Ellen Taplin; Peter M Venner; Bertrand Tombal
Journal:  N Engl J Med       Date:  2014-06-01       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.